Company Petros Pharmaceuticals

Equities

PTPI

US71678J2096

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
0.6399 ^USD	0.00%		-4.51%	-54.62%

Apr. 23	Petros, Lemonaid Health Collaborate to Expand Stendra Availability	MT
Apr. 23	Petros Pharmaceuticals, Inc. Expands Online Distribution for Prescription STENDRA Through New Agreement with Lemonaid Health	CI

Business Summary

Petros Pharmaceuticals, Inc. is a pharmaceutical company focused on men's health therapeutics with a range of commercial capabilities including sales, marketing, regulatory and medical affairs, finance, trade relations, pharmacovigilance, market access relations, manufacturing, and distribution. The Company is also focused on identifying, developing, acquiring, and commercializing therapeutics for men's health issues, including, erectile dysfunction (ED), endothelial dysfunction, psychosexual and psychosocial ailments, peyronie's disease, hormone health, and substance use disorders. The Company also markets its own line of ED products in the form of vacuum erection device (VED) products through its subsidiaries, Timm Medical, Inc. In addition, its ED products, the Company is focused on identifying and developing other pharmaceuticals to advance men's health, which is H100, which is the topical formulation candidate for the treatment of acute peyronie's disease.

Number of employees: 21

Sales per Business

USD in Million	2022	Weight	2023	Weight	Delta
Medical Devices 60.7 %	3	54.4 %	4	60.7 %	+8.55%
Prescription Medications 39.3 %	3	45.6 %	2	39.3 %	-16.39%

Sales per region

USD in Million	2022	Weight	2023	Weight	Delta
United States 77.7 %	5	80.1 %	5	77.7 %	-5.68%
International 22.3 %	1	19.9 %	1	22.3 %	+8.62%

Managers

Managers	Title	Age	Since
Shulman John David CEO	Chief Executive Officer	61	-
Fady Boctor PSD	President	47	20-11-30
Mitchell Arnold AUD	Comptroller/Controller/Auditor	61	18-12-31

Members of the board

Members of the board	Title	Age	Since
Shulman John David CEO	Chief Executive Officer	61	-
Bruce Bernstein BRD	Director/Board Member	60	20-11-30
Joshua Silverman BRD	Director/Board Member	53	19-12-31
Wayne Walker BRD	Director/Board Member	65	20-11-30
Gregory Bradley BRD	Director/Board Member	64	20-11-30

Shareholders

Name	Equities	%	Valuation
Juggernaut Management LLC 35.89 %	789,969	35.89 %	1 M $
Fady Boctor 2.255 %	49,645	2.255 %	73 475 $
Vanguard Group, Inc. (Subfiler) 1.445 %	31,811	1.445 %	47 080 $
Virtu Financial LLC 1.128 %	24,825	1.128 %	36 741 $
Schonfeld Strategic Advisors LLC 1.027 %	22,600	1.027 %	33 448 $
BlackRock Institutional Trust Co. NA 0.7539 %	16,594	0.7539 %	24 559 $
Joshua Silverman 0.5106 %	11,238	0.5106 %	16 632 $
Geode Capital Management LLC 0.4771 %	10,502	0.4771 %	15 543 $
Tower Research Capital LLC 0.4147 %	9,127	0.4147 %	13 508 $
Bruce Bernstein 0.3792 %	8,347	0.3792 %	12 354 $